European Heart Journal-Cardiovascular Pharmacotherapy

European Heart Journal-Cardiovascular Pharmacotherapy is a peer-reviewed journal of the European Society of Cardiology, established in 2015 and published by Oxford University Press under the ISSN 2055-6837, covering clinical cardiovascular pharmacology, with a 2025 Journal Impact Factor of 8.2 and a rank of 20 of 356 in pharmacology and pharmacy《欧洲心脏杂志－心血管药物治疗》（European Heart Journal-Cardiovascular Pharmacotherapy）是（European Society of Cardiology）的同行评审期刊，2015 年创办、由（Oxford University Press）出版，刊号 2055-6837，覆盖临床心血管药理学，2025 年影响因子为 8.2，在药理学与药学类 356 种期刊中列第 20 位。

Scope

• It is an official journal of the European Society of Cardiology and of the ESC Working Group on Cardiovascular Pharmacotherapy, and it accepts manuscripts from all parts of the world by members and non-members alike该刊是（European Society of Cardiology）及其心血管药物治疗工作组的官方期刊，接受来自世界各地、无论是否为学会会员的作者投稿。
• The journal is an international, English-language, peer-reviewed title with a specific focus on clinical cardiovascular pharmacology, publishing original articles concerning clinical research该刊是以英文出版的国际同行评审期刊，专门聚焦临床心血管药理学，发表以临床研究为主的原创论文。
• Its subject matter covers cardiovascular drug therapy across the main disease areas of cardiology, including antithrombotic therapy, lipid lowering, antihypertensive treatment, heart failure pharmacotherapy and antiarrhythmic therapy其主题覆盖心脏病学主要疾病领域的心血管药物治疗，包括抗栓治疗、降脂治疗、降压治疗、心力衰竭药物治疗与抗心律失常治疗。
• Work on drug safety, pharmacological mechanisms relevant to cardiovascular medicine and the translation of pharmacological findings into clinical practice also falls within its remit药物安全性、与心血管医学相关的药理机制以及把药理学发现转化为临床实践的工作，同样属于其收稿范围。
• Case reports are not published by this journal and are directed to European Heart Journal - Case Reports, the online-only, fully open access journal of the society该刊不发表病例报告，此类稿件被引导至仅在线发行、完全开放获取的学会期刊（European Heart Journal - Case Reports）。
• The journal appears eight times a year, and in 2025 the volume carried issues in January, March, May, July, August, September, November and December该刊每年出版 8 期；2025 年该卷的出版月份为 1 月、3 月、5 月、7 月、8 月、9 月、11 月与 12 月。

History

• The journal was established in 2015 as the official peer-reviewed journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy, within the wider European Heart Journal family该刊于 2015 年创办，作为（European Society of Cardiology）与（ESC Working Group on Cardiovascular Pharmacotherapy）的官方同行评审期刊，隶属于（European Heart Journal）期刊群。
• Its first editor-in-chief was Stefan Agewall, who took up the role as the journal was being built and served in it until he stepped down at the start of 2026其首任主编为 Stefan Agewall，其在刊物筹备阶段即出任此职，并任职至 2026 年初卸任。
• The farewell to the outgoing editor-in-chief appeared in volume 12, issue 2 of the journal, in which colleagues recorded his service since 2014前任主编的告别文章刊于该刊第 12 卷第 2 期，其中同行记述了其自 2014 年以来的工作。
• From 2026 the editor-in-chief is Bianca Rocca, who leads a renewed editorial board based in Italy, the United Kingdom and elsewhere in Europe自 2026 年起，主编为 Bianca Rocca，其主持更新的编委会，成员来自意大利、英国与欧洲其他地区。
• Impact factors were 6.617 in 2021, 11.177 in 2022, 6.1 in 2024 and 8.2 in 2025, when the journal ranked 28th of 237 titles in cardiac and cardiovascular systems影响因子为 2021 年 6.617、2022 年 11.177、2024 年 6.1、2025 年 8.2，当年在心脏与心血管系统类 237 种期刊中列第 28 位。
• The journal is published by Oxford University Press on behalf of the European Society of Cardiology, and its articles carry the publisher's digital object identifier prefix该刊由（Oxford University Press）代表（European Society of Cardiology）出版，论文使用该出版方的数字对象标识符前缀。

Editors

• The editor-in-chief is Professor Bianca Rocca of Libera Universita Mediterranea-LUM in Casamassima, Bari, Italy, who is a clinical pharmacologist现任主编为（Libera Universita Mediterranea-LUM，位于意大利 Bari 的 Casamassima）的 Bianca Rocca 教授，其专业为临床药理学。
• The journal's editorial office is operated by a dedicated editorial services provider, which coordinates submission, review and production on behalf of the editor-in-chief该刊编辑部由专门编辑服务机构运营，代表主编统筹投稿、评审与制作流程。
• Peer review is single anonymised, meaning that the identities of authors are known to the editor and the reviewers while the identities of reviewers are hidden from authors同行评审采用单盲方式，即编辑与审稿人知晓作者身份，而审稿人身份对作者保密。
• As an official journal of the society, it draws its reviewers from the international cardiovascular pharmacology community, and manuscripts are accepted from authors both inside and outside the society作为学会官方期刊，其审稿人来自国际心血管药理学界，且学会内外作者的稿件均可投稿。
• The editor-in-chief is supported by an editorial board of cardiologists, pharmacologists and clinical pharmacologists, whose names and affiliations are published on the journal's editorial board page主编由心脏病学、药理学与临床药理学专家组成的编委会支持，其姓名与所属机构在期刊编委页公布。
• Because case reports and related clinical images are outside its remit, the journal directs such submissions to European Heart Journal - Case Reports instead由于病例报告及相关临床影像不属其范围，该刊将此类投稿引导至（European Heart Journal - Case Reports）。